Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Tecentriq Positive But Not Perfect In IMpower130 First-line Lung Cancer Study

Executive Summary

Combination with Abraxane demonstrates an overall survival benefit on top of progression-free survival, but Merck's competing Keytruda has set a high benchmark for first-line metastatic lung cancer.

Advertisement

Related Content

Mystic Miss Not Make Or Break For Imfinzi
Pharma Q3 Results Preview: Merck Vs. Bristol In IO Showdown
IMpower132 Casts More Doubt On Roche's Tecentriq In First-Line NSCLC
Roche's IMpower130 Met Co-Primary Endpoints, Lifting ASCO Suspense
Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124039

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel